DOCSLIB.ORG

Molecular Variants of Soluble Guanylyl Cyclase Affecting

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Variants of Soluble Guanylyl Cyclase Affecting Advance Publication by-J-STAGE Circulation Journal REVIEW Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Molecular Variants of Soluble Guanylyl Cyclase Affecting Cardiovascular Risk Jana Wobst; Philipp Moritz Rumpf, MD; Tan An Dang; Maria Segura-Puimedon, PhD; Jeanette Erdmann, PhD; Heribert Schunkert, MD Soluble guanylyl cyclase (sGC) is the physiological receptor for nitric oxide (NO) and NO-releasing drugs, and is a key enzyme in several cardiovascular signaling pathways. Its activation induces the synthesis of the second mes- senger cGMP. cGMP regulates the activity of various downstream proteins, including cGMP-dependent protein kinase G, cGMP-dependent phosphodiesterases and cyclic nucleotide gated ion channels leading to vascular relaxation, inhibition of platelet aggregation, and modified neurotransmission. Diminished sGC function contributes to a number of disorders, including cardiovascular diseases. Knowledge of its regulation is a prerequisite for under- standing the pathophysiology of deficient sGC signaling. In this review we consolidate the available information on sGC signaling, including the molecular biology and genetics of sGC transcription, translation and function, including the effect of rare variants, and present possible new targets for the development of personalized medicine in vascu- lar diseases. Key Words: Cardiovascular disease; Cyclic guanosine-3’,5’-monophosphate (cGMP); Molecular variants; Nitric oxide (NO); Soluble guanylyl cyclase (sGC) he major components of the nitric oxide (NO)/cyclic varied and include vascular smooth muscle cell (VSMC) relax- guanosine-3’,5’-monophosphate (cGMP) pathway ation,11 inhibited platelet aggregation12 and modified neuro- T were identified in the late 1980s.1,2 NO is biosynthe- transmission,13 for example. sized endogenously through sequential oxidation of the amino acid L-arginine by an enzyme family called the NO synthases (NOS).3 Three isoforms of NOS with different tissue distribu- sGC Subunits tions are known: neuronal NOS (nNOS/NOS1), inducible NOS sGC is composed of 2 subunits: α and β.14 In 1981 Gerzer et in macrophages (iNOS/NOS2) and endothelial NOS (eNOS/ al showed that sGC contains a heme in form of ferroprotopor- NOS3).4 In the cardiovascular system, eNOS is the main source phyrin IX.15 However, it was unknown for a long time whether of NO production.5,6 The formation of NO by eNOS is increased this prosthetic heme group is sandwiched between the α and β by various stimuli such as platelet-derived factors, shear stress, subunits or whether it exclusively binds to the β subunit. In acetylcholine, and cytokines.7 1997, Zhao and Marletta demonstrated the ferrous heme to be NO mediates its functions through its primary receptor: sol- ligated to the N-terminal part of the β subunit at His105.16 uble guanylyl cyclase (sGC). Together with the adenylate In humans, 2 types of each subunit exist: α1 and α2 for the cyclases, sGC belongs to the class III purine nucleotidyl cyclase α subunit and β1 and β2 for the β subunit. These 4 proteins are family.8 Binding of NO to the heme moiety of sGC induces encoded by 4 distinct genes: GUCY1A3 (α1), GUCY1A2 (α2); the transition from basal to activated sGC. Activated sGC GUCY1B3 (β1), and GUCY1B2 (β2). The genes for human α1 converts guanosine-5’-triphosphate (GTP) to cGMP and pyro- and β1 have been mapped to chromosome 4,17 and those encod- phosphate (PPi).9 PPi is emerging as a major factor in prevent- ing α2 and β2 to chromosomes 1118 and 13,19 respectively ing vascular calcification.10 cGMP acts as a ubiquitous second (Table 1). Dimerization of the enzyme is a prerequisite for its messenger in intracellular signaling cascades, which serves to catalytic activity.20 Both α subunits give rise to a functional regulate the activity of a number of downstream proteins, enzyme when coexpressed with β1 (ie, both α1/β1 and α2/β1 including cGMP-dependent protein kinase G (PKG), cGMP- heterodimers are activated by NO).21 Although heterodimers dependent phosphodiesterases (PDE) and cyclic nucleotide seem to be the preferred form in cells, the features that deter- gated ion channels. The signals propagated through cGMP are mine this preference, and any possible role for homodimers, Received January 13, 2015; accepted January 14, 2015; released online February 6, 2015 Department of Cardiovascular Diseases, German Heart Center Munich, Technical University Munich, Munich (J.W., P.M.R., T.A.D., H.S.); Institute for Integrative and Experimental Genomics, University of Lübeck, Lübeck (M.S.-P., J.E.); German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck (J.E.); and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich (H.S.), Germany Mailing address: Heribert Schunkert, Professor Dr, MD, Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Lazarettstr. 36, 80636 Munich, Germany. E-mail: [email protected] ISSN-1346-9843 doi: 10.1253/circj.CJ-15-0025 All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: [email protected] Advance Publication by-J-STAGE WOBST J et al. Table 1. Overview of Human Soluble Guanylyl Cyclase Subunit Isoforms Chromosomal Protein size Gene Transcript variant Exons Isoform location (aa) GUCY1A3 4q31.1-q31.2 GUCY1A3-Tr1 11 α1-IsoA 690 GUCY1A3-Tr2 10 GUCY1A3-Tr3 10 GUCY1A3-Tr4 8 GUCY1A3-Tr5 10 α1-IsoB 455 GUCY1A3-Tr7 9 α1-IsoD 624 GUCY1A3-Tr8 10 α1-IsoA 690 GUCY1A2 11q21-q22 GUCY1A3-Tr1 9 α2i 763 GUCY1A3-Tr2 8 α2 732 GUCY1B3 4q31.3-q33 GUCY1B3-Tr1 15 β1-Iso1 641 GUCY1B3-Tr2 14 β1-Iso2 619 GUCY1B3-Tr3 15 β1-Iso3 599 GUCY1B3-Tr4 16 β1-Iso4 594 GUCY1B3-Tr5 14 β1-Iso5 586 GUCY1B3-Tr6 13 β1-Iso6 551 GUCY1B2 13q14.3 – 17 – 617 are not fully defined. Koglin et al could show thatβ 2 does not which likely affects mRNA stability. exhibit cyclase activity when expressed with either α1 or α2 but In mammals, a splice variant of α2 (α2i) generates a dominant that β2 is active in the absence of an α subunit.22 This implies negative variant when forming a dimer with β1 because α2i con- that the β2 protein can function as a homodimer ex vivo. How- tains an in-frame insertion of 31 amino acids within the cata- ever, the physiological role of the β2 subunit in cGMP signal- lytic domain.37 Concerning β2, the NCBI nucleotide database ing remains elusive. By contrast, Zabel et al were able to just provides information on a single human β2 transcript overexpress α1/α1 and β1/β1 homodimers in Sf9 cells, both (Table 1). Because at least 3 different β2 transcripts have been being catalytically inactive.23 observed in humans38–40 and different β2 isoforms have been cloned from rats,41 there is evidence that β2 also exists as dif- ferent isoforms in humans. Alternative Splicing Recently, Martin et al36 conducted a study of the role of alter- Diminished expression and function of sGC contributes to the native splicing of GUCY1A3 and GUCY1B3 sGC in healthy pathogenesis of several cardiovascular disorders such as coro- and diseased human vascular tissue. As splicing regulation of nary artery disease (CAD), atherosclerosis and hypertension.24 sGC and its biological role in vascular tissue has not been Most recently, the chromosomal locus harboring GUCY1A3 previously examined in vivo, they were the first to show splic- (α1) and GUCY1B3 (β1) was shown to contain genetic variants ing diminishing sGC function. Using a semiquantitative with genome-wide significant association to CAD and hyper- reverse transcriptase PCR approach, they uncovered various tension.25–27 Thus, the GUCY1A3/GUCY1B3 locus adds to the GUCY1A3 and GUCY1B3 splice variants in human aorta. growing list of those contributing to CAD and myocardial Quantifying the total levels of GUCY1A3 and GUCY1B3 sGC infarction (MI) risk.28,29 transcripts using quantitative PCR revealed a 3.2- and 2.3-fold The expression of sGC subunits is modulated at different increase in, respectively, GUCY1A3 and GUCY1B3 mRNA in levels, including inhibition of transcription,30,31 destabilization aortas with aneurysms compared with healthy control aortas. of mRNA,32,33 and protein degradation.34 The role of alterna- Interestingly, the aortas with aneurysms demonstrated decreased tive splicing in this process still needs to be uncovered. Precise sGC activity that correlated with increased expression of dys- understanding of sGC splicing regulation could serve as a tar- functional sGC splice variants, because the composition of the get for new therapeutic interventions and help to personalize splice forms in the aortas with aneurysms differed from that in sGC-targeting therapies in the treatment of vascular disease. control aortas (Figure 1). As demonstrated by several studies, human α1, α2 and β1 exist GUCY1A3-Tr1 coding for α1-IsoA and GUCY1A3-Tr7 cod- as different isoforms because of alternatively spliced transcript ing for α1-IsoD were higher in diseased aortas. α1-IsoD lacks variants35–37 (Table 1). Besides several predicted sequences, 66 C-terminal amino acids and has impaired enzymatic activ- NCBI nucleotide database research reveals a total of 7 alter- ity. In contrast, the level GUCY1A3-Tr5 coding for α1-IsoB natively spliced human transcript variants for GUCY1A3, 2 for was lower in the aneurysm samples. α1-IsoB is 235 amino GUCY1A2 and 6 for GUCY1B3. In the case of GUCY1A2 (α2 acids shorter at the N-terminus and oxidation resistant.42 The and α2i) and GUCY1B3 (β1-Iso1 to Iso6), each transcript vari- immunoprecipitation studies and activity evaluation presented ant codes for 1 unique isoform. However, the 7 alternatively by Martin et al clearly demonstrated that α1-IsoB forms a func- spliced variants of GUCY1A3 only code for 3 different iso- tional heterodimer with β1 subunit in aorta in vivo.
Load more

Recommended publications
  • Birthdating of Myenteric Neuron Subtypes in the Small Intestine of the Mouse
    RESEARCH ARTICLE Birthdating of Myenteric Neuron Subtypes in the Small Intestine of the Mouse Annette J. Bergner,1 Lincon A. Stamp,1 David G. Gonsalvez,1 Margaret B. Allison,2,3 David P. Olson,4 Martin G. Myers Jr,2,3,5 Colin R. Anderson,1 and Heather M. Young1* 1Department of Anatomy & Neuroscience, University of Melbourne, Victoria, Australia 2Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA 3Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA 4Division of Endocrinology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA 5Department of Neuroscience Graduate Program, University of Michigan, Ann Arbor, Michigan, USA ABSTRACT vast majority of myenteric neurons had exited the cell There are many different types of enteric neurons. Pre- cycle by P10. We did not observe any EdU1/NOS11 vious studies have identified the time at which some myenteric neurons in the small intestine of adult mice enteric neuron subtypes are born (exit the cell cycle) in following EdU injection at E10.5 or E11.5, which was the mouse, but the birthdates of some major enteric unexpected, as previous studies have shown that NOS1 neuron subtypes are still incompletely characterized or neurons are present in E11.5 mice. Studies using the unknown. We combined 5-ethynynl-20-deoxyuridine proliferation marker Ki67 revealed that very few NOS1 (EdU) labeling with antibody markers that identify myen- neurons in the E11.5 and E12.5 gut were proliferating. teric neuron subtypes to determine when neuron sub- However, Cre-lox-based genetic fate-mapping revealed types are born in the mouse small intestine.
    [Show full text]
  • The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’S Disease
    life Review The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’s Disease Gianfranco Natale 1,2,* , Larisa Ryskalin 1 , Gabriele Morucci 1 , Gloria Lazzeri 1, Alessandro Frati 3,4 and Francesco Fornai 1,4 1 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy; [email protected] (L.R.); [email protected] (G.M.); [email protected] (G.L.); [email protected] (F.F.) 2 Museum of Human Anatomy “Filippo Civinini”, University of Pisa, 56126 Pisa, Italy 3 Neurosurgery Division, Human Neurosciences Department, Sapienza University of Rome, 00135 Rome, Italy; [email protected] 4 Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Neuromed, 86077 Pozzilli, Italy * Correspondence: [email protected] Abstract: The gastrointestinal (GI) tract is provided with a peculiar nervous network, known as the enteric nervous system (ENS), which is dedicated to the fine control of digestive functions. This forms a complex network, which includes several types of neurons, as well as glial cells. Despite extensive studies, a comprehensive classification of these neurons is still lacking. The complexity of ENS is magnified by a multiple control of the central nervous system, and bidirectional communication between various central nervous areas and the gut occurs. This lends substance to the complexity of the microbiota–gut–brain axis, which represents the network governing homeostasis through nervous, endocrine, immune, and metabolic pathways. The present manuscript is dedicated to Citation: Natale, G.; Ryskalin, L.; identifying various neuronal cytotypes belonging to ENS in baseline conditions.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Soluble Guanylate Cyclase B1-Subunit Expression Is Increased in Mononuclear Cells from Patients with Erectile Dysfunction
    International Journal of Impotence Research (2006) 18, 432–437 & 2006 Nature Publishing Group All rights reserved 0955-9930/06 $30.00 www.nature.com/ijir ORIGINAL ARTICLE Soluble guanylate cyclase b1-subunit expression is increased in mononuclear cells from patients with erectile dysfunction PJ Mateos-Ca´ceres1, J Garcia-Cardoso2, L Lapuente1, JJ Zamorano-Leo´n1, D Sacrista´n1, TP de Prada1, J Calahorra2, C Macaya1, R Vela-Navarrete2 and AJ Lo´pez-Farre´1 1Cardiovascular Research Unit, Cardiovascular Institute, Hospital Clı´nico San Carlos, Madrid, Spain and 2Urology Department, Fundacio´n Jime´nez Diaz, Madrid, Spain The aim was to determine in circulating mononuclear cells from patients with erectile dysfunction (ED), the level of expression of endothelial nitric oxide synthase (eNOS), soluble guanylate cyclase (sGC) b1-subunit and phosphodiesterase type-V (PDE-V). Peripheral mononuclear cells from nine patients with ED of vascular origin and nine patients with ED of neurological origin were obtained. Fourteen age-matched volunteers with normal erectile function were used as control. Reduction in eNOS protein was observed in the mononuclear cells from patients with ED of vascular origin but not in those from neurological origin. Although sGC b1-subunit expression was increased in mononuclear cells from patients with ED, the sGC activity was reduced. However, only the patients with ED of vascular origin showed an increased expression of PDE-V. This work shows for the first time that, independently of the aetiology of ED, the expression of sGC b1-subunit was increased in circulating mononuclear cells; however, the expression of both eNOS and PDE-V was only modified in the circulating mononuclear cells from patients with ED of vascular origin.
    [Show full text]
  • Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation
    International Journal of Molecular Sciences Review Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation Elizabeth C. Wittenborn and Michael A. Marletta * California Institute for Quantitative Biosciences, Departments of Chemistry and of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA; [email protected] * Correspondence: [email protected] Abstract: The enzyme soluble guanylate cyclase (sGC) is the prototypical nitric oxide (NO) receptor in humans and other higher eukaryotes and is responsible for transducing the initial NO signal to the secondary messenger cyclic guanosine monophosphate (cGMP). Generation of cGMP in turn leads to diverse physiological effects in the cardiopulmonary, vascular, and neurological systems. Given these important downstream effects, sGC has been biochemically characterized in great detail in the four decades since its discovery. Structures of full-length sGC, however, have proven elusive until very recently. In 2019, advances in single particle cryo–electron microscopy (cryo-EM) enabled visualization of full-length sGC for the first time. This review will summarize insights revealed by the structures of sGC in the unactivated and activated states and discuss their implications in the mechanism of sGC activation. Keywords: nitric oxide; soluble guanylate cyclase; cryo–electron microscopy; enzyme structure Citation: Wittenborn, E.C.; Marletta, 1. Introduction M.A. Structural Perspectives on the Soluble guanylate cyclase (sGC) is a nitric oxide (NO)-responsive enzyme that serves Mechanism of Soluble Guanylate as a source of the secondary messenger cyclic guanosine monophosphate (cGMP) in Cyclase Activation. Int. J. Mol. Sci. humans and other higher eukaryotes [1]. Upon NO binding to sGC, the rate of cGMP 2021, 22, 5439.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Nitric Oxide Enhances the Sensitivity of Alpaca Melanocytes to Respond to A-Melanocyte-Stimulating Hormone by Up-Regulating Melanocortin-1 Receptor
    Biochemical and Biophysical Research Communications 396 (2010) 849–853 Contents lists available at ScienceDirect Biochemical and Biophysical Research Communications journal homepage: www.elsevier.com/locate/ybbrc Nitric oxide enhances the sensitivity of alpaca melanocytes to respond to a-melanocyte-stimulating hormone by up-regulating melanocortin-1 receptor Yanjun Dong, Jing Cao, Haidong Wang, Jie Zhang, Zhiwei Zhu, Rui Bai, HuanQing Hao, Xiaoyan He, Ruiwen Fan, Changsheng Dong * College of Animal Science and Technology, Shanxi Agricultural University, 030801 Taigu, Shanxi, China article info abstract Article history: Nitric oxide (NO) and a-melanocyte-stimulating hormone (a-MSH) have been correlated with the syn- Received 25 April 2010 thesis of melanin. The NO-dependent signaling of cellular response to activate the hypothalamopituitary Available online 6 May 2010 proopiomelanocortin system, thereby enhances the hypophysial secretion of a-MSH to stimulate a-MSH- receptor responsive cells. In this study we investigated whether an NO-induced pathway can enhance the Keywords: ability of the melanocyte to respond to a-MSH on melanogenesis in alpaca skin melanocytes in vitro.Itis Nitric oxide (NO) important for us to know how to enhance the coat color of alpaca. We set up three groups for experiments a-Melanocyte-stimulating hormone using the third passage number of alpaca melanocytes: the control cultures were allowed a total of 5 days (a-MSH) growth; the UV group cultures like the control group but the melanocytes were then irradiated everyday Melanocortin-1 receptor (MC1R) 2 Alpaca (once) with 312 mJ/cm of UVB; the UV + L-NAME group is the same as group UV but has the addition of Melanocyte 300 lM L-NAME (every 6 h).
    [Show full text]
  • Allosteric Activation of the Nitric Oxide Receptor Soluble Guanylate Cyclase
    RESEARCH ARTICLE Allosteric activation of the nitric oxide receptor soluble guanylate cyclase mapped by cryo-electron microscopy Benjamin G Horst1†, Adam L Yokom2,3†, Daniel J Rosenberg4,5, Kyle L Morris2,3‡, Michal Hammel4, James H Hurley2,3,4,5*, Michael A Marletta1,2,3* 1Department of Chemistry, University of California, Berkeley, Berkeley, United States; 2Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States; 3Graduate Group in Biophysics, University of California, Berkeley, Berkeley, United States; 4Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, United States; 5California Institute for Quantitative Biosciences, University of California, Berkeley, Berkeley, United States Abstract Soluble guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) in mammalian nitric oxide signaling. We determined structures of full-length Manduca sexta sGC in both inactive and active states using cryo-electron microscopy. NO and the sGC-specific stimulator YC-1 induce a 71˚ rotation of the heme-binding b H-NOX and PAS domains. Repositioning of the b *For correspondence: H-NOX domain leads to a straightening of the coiled-coil domains, which, in turn, use the motion to [email protected] (JHH); move the catalytic domains into an active conformation. YC-1 binds directly between the b H-NOX [email protected] (MAM) domain and the two CC domains. The structural elongation of the particle observed in cryo-EM was †These authors contributed corroborated in solution using small angle X-ray scattering (SAXS). These structures delineate the equally to this work endpoints of the allosteric transition responsible for the major cyclic GMP-dependent physiological Present address: ‡MRC London effects of NO.
    [Show full text]
  • A Nitric Oxide/Cysteine Interaction Mediates the Activation of Soluble Guanylate Cyclase
    A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase Nathaniel B. Fernhoffa,1, Emily R. Derbyshirea,1,2, and Michael A. Marlettaa,b,c,3 Departments of aMolecular and Cell Biology and bChemistry, University of California, Berkeley, CA 94720; and cCalifornia Institute for Quantitative Biosciences and Division of Physical Biosciences, Lawrence Berkeley National Laboratory, Berkeley, CA 94720 Contributed by Michael A. Marletta, October 1, 2009 (sent for review August 22, 2009) Nitric oxide (NO) regulates a number of essential physiological pro- high activity of the xsNO state rapidly reverts to the low activity of cesses by activating soluble guanylate cyclase (sGC) to produce the the 1-NO state. Thus, all three sGC states (basal, 1-NO, and xsNO) second messenger cGMP. The mechanism of NO sensing was previ- can be prepared and studied in vitro (7, 8). Importantly, these ously thought to result exclusively from NO binding to the sGC heme; results define two different states of purified sGC with heme bound however, recent studies indicate that heme-bound NO only partially NO (7, 8), one with a high activity and one with a low activity. activates sGC and additional NO is involved in the mechanism of Further evidence for a non-heme NO binding site was obtained maximal NO activation. Furthermore, thiol oxidation of sGC cysteines by blocking the heme site with the tight-binding ligand butyl results in the loss of enzyme activity. Herein the role of cysteines in isocyanide, and then showing that NO still activated the enzyme NO-stimulated sGC activity investigated. We find that the thiol mod- (14).
    [Show full text]
  • Supplementary Materials
    Supplementary Materials + - NUMB E2F2 PCBP2 CDKN1B MTOR AKT3 HOXA9 HNRNPA1 HNRNPA2B1 HNRNPA2B1 HNRNPK HNRNPA3 PCBP2 AICDA FLT3 SLAMF1 BIC CD34 TAL1 SPI1 GATA1 CD48 PIK3CG RUNX1 PIK3CD SLAMF1 CDKN2B CDKN2A CD34 RUNX1 E2F3 KMT2A RUNX1 T MIXL1 +++ +++ ++++ ++++ +++ 0 0 0 0 hematopoietic potential H1 H1 PB7 PB6 PB6 PB6.1 PB6.1 PB12.1 PB12.1 Figure S1. Unsupervised hierarchical clustering of hPSC-derived EBs according to the mRNA expression of hematopoietic lineage genes (microarray analysis). Hematopoietic-competent cells (H1, PB6.1, PB7) were separated from hematopoietic-deficient ones (PB6, PB12.1). In this experiment, all hPSCs were tested in duplicate, except PB7. Genes under-expressed or over-expressed in blood-deficient hPSCs are indicated in blue and red respectively (related to Table S1). 1 C) Mesoderm B) Endoderm + - KDR HAND1 GATA6 MEF2C DKK1 MSX1 GATA4 WNT3A GATA4 COL2A1 HNF1B ZFPM2 A) Ectoderm GATA4 GATA4 GSC GATA4 T ISL1 NCAM1 FOXH1 NCAM1 MESP1 CER1 WNT3A MIXL1 GATA4 PAX6 CDX2 T PAX6 SOX17 HBB NES GATA6 WT1 SOX1 FN1 ACTC1 ZIC1 FOXA2 MYF5 ZIC1 CXCR4 TBX5 PAX6 NCAM1 TBX20 PAX6 KRT18 DDX4 TUBB3 EPCAM TBX5 SOX2 KRT18 NKX2-5 NES AFP COL1A1 +++ +++ 0 0 0 0 ++++ +++ ++++ +++ +++ ++++ +++ ++++ 0 0 0 0 +++ +++ ++++ +++ ++++ 0 0 0 0 hematopoietic potential H1 H1 H1 H1 H1 H1 PB6 PB6 PB7 PB7 PB6 PB6 PB7 PB6 PB6 PB6.1 PB6.1 PB6.1 PB6.1 PB6.1 PB6.1 PB12.1 PB12.1 PB12.1 PB12.1 PB12.1 PB12.1 Figure S2. Unsupervised hierarchical clustering of hPSC-derived EBs according to the mRNA expression of germ layer differentiation genes (microarray analysis) Selected ectoderm (A), endoderm (B) and mesoderm (C) related genes differentially expressed between hematopoietic-competent (H1, PB6.1, PB7) and -deficient cells (PB6, PB12.1) are shown (related to Table S1).
    [Show full text]
  • GUCY2F Protein Recombinant Human Protein Expressed in Sf9 Cells
    Catalog # Aliquot Size G12-31G-20 20 µg G12-31G-50 50 µg GUCY2F Protein Recombinant human protein expressed in sf9 cells Catalog # G12-31G Lot # U1858-3 Product Description Purity Recombinant human GUCY2F (367-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The gene accession number is BC156674. The purity of GUCY2F protein was determined to be >70% by Gene Aliases densitometry, GUCY2F approx. MW 110kDa. CYGF, GC-F, GUC2DL, GUC2F, RETGC-2, ROS-GC2 Formulation Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. Storage and Stability Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Scientific Background Guanylate cyclase 2F (GUCY2F) belongs to the adenylyl cyclase class-4/guanylyl cyclase family which also includes GUCY2D. Both GUCY2F and GUCY2D are responsible for the replenishment of cGMP in photoreceptors after exposure to light and are required for the normal kinetics of photoreceptor sensitivity and recovery, although disease mutations are restricted to GUCY2F Protein Full-length recombinant human protein expressed in sf9 cells GUCY2D. Catalog # G12-31G References Lot # U1858-3 1. Goraczniak R, et al: Structural and functional characteri- Purity >70% Concentration 0.05 µg/µl zation of a second subfamily member of the calcium- Stability 1yr at –70oC from date of shipment modulated bovine rod outer segment membrane Storage & Shipping Store product at –70oC.
    [Show full text]